- Home
- GUTS vs RFL Comparison
GUTS vs RFL Comparison
Compare GUTS & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GUTS
- RFL
- Stock Information
- Founded
- GUTS 2010
- RFL 2017
- Country
- GUTS United States
- RFL United States
- Employees
- GUTS N/A
- RFL N/A
- Industry
- GUTS
- RFL Real Estate
- Sector
- GUTS
- RFL Finance
- Exchange
- GUTS NYSE
- RFL Nasdaq
- Market Cap
- GUTS 58.8M
- RFL 48.4M
- IPO Year
- GUTS 2024
- RFL N/A
- Fundamental
- Price
- GUTS $1.58
- RFL $1.93
- Analyst Decision
- GUTS Buy
- RFL
- Analyst Count
- GUTS 1
- RFL 0
- Target Price
- GUTS $10.00
- RFL N/A
- AVG Volume (30 Days)
- GUTS 930.5K
- RFL 462.2K
- Earning Date
- GUTS 08-13-2025
- RFL 06-11-2025
- Dividend Yield
- GUTS N/A
- RFL N/A
- EPS Growth
- GUTS N/A
- RFL N/A
- EPS
- GUTS N/A
- RFL N/A
- Revenue
- GUTS $60,000.00
- RFL $732,000.00
- Revenue This Year
- GUTS N/A
- RFL N/A
- Revenue Next Year
- GUTS N/A
- RFL N/A
- P/E Ratio
- GUTS N/A
- RFL N/A
- Revenue Growth
- GUTS N/A
- RFL 35.56
- 52 Week Low
- GUTS $0.87
- RFL $1.27
- 52 Week High
- GUTS $4.92
- RFL $3.19
- Technical
- Relative Strength Index (RSI)
- GUTS 42.52
- RFL 51.93
- Support Level
- GUTS $1.54
- RFL $1.56
- Resistance Level
- GUTS $1.82
- RFL $1.84
- Average True Range (ATR)
- GUTS 0.18
- RFL 0.20
- MACD
- GUTS -0.07
- RFL -0.03
- Stochastic Oscillator
- GUTS 5.06
- RFL 28.68
About GUTS FRACTYL HEALTH INC
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.
About RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc is a holding company with interests in clinical and early-stage pharmaceutical companies. Its primary focus is to expand its investment portfolio through opportunistic investments including therapeutics, which address high unmet medical needs. Through the companies it has invested in, the company is focused on; developing Trappsol Cyclo its clinical program, developing instruments to advance minimally invasive surgeries, preclinical cancer metabolism research operations, and developing pharmaceutical-grade technology Unlokt for third-party cannabis manufacturers. It also holds and manages commercial real estate assets in Jerusalem, Israel. The company's reportable segments are; Infusion Technology, which derives maximum revenue, Healthcare, and Real Estate.